Observational studyEye (London, England)2025
Clinical outcomes with a new diffractive multifocal intraocular lens optimized by the dynamic light utilization algorithm.
Observational study in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Update on Intraocular Lens Technology for Presbyopia Correction and Visual Outcomes.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesTo evaluate the refractive outcomes, optical performance, and the quality of vision in patients implanted with a new diffractive intraocular lens (IOL), the Intensity Hanita. SUBJECTS/
methodsThis observational, prospective, longitudinal study included 64 eyes underwent bilateral cataract surgery with the Intensity IOL (Hanita Israel) implantation. Main outcome measures after 6 months were the following visual acuities (VAs) of uncorrected and corrected distance (UDVA and CDVA), uncorrected and distance corrected intermediate VAs (UIVA and DCIVA), uncorrected and distance corrected near (UNVA and DCNVA), refraction, slitlamp biomicroscopy, defocus curve (DFC), high ocular aberrations (HOA), contrast sensitivity (CS), optical quality, subjective quality of vision (QoV) and near activity visual questionnaires (NAVQ).
resultsSixty-six percent of eyes having UDVA 0.10 logMAR or better. DFC showed maximum vision at distance (0.02 ± 0.07 LogMAR at 0.0 D), with flat decline through intermediate and near vision (0.11 ± 0.08 LogMAR at -1.5 D and 0.12 ± 0.12 at -2.5 D). No significant changes in CS were found (all spatial frequencies, p ≥ 0.06). The RMS of HOA, coma, trefoil, and SA were 0.21 ± 0.10, 0.10 ± 0.06, 0.11 ± 0.07, and 0.00 ± 0.04 μm and the Strehl ratio was 0.12 ± .04 at 6 months. Subjective symptoms (halos and glare) were reported mild but well tolerated, not causing significant disturbance in daily activities. The NAVQ showed high levels of satisfaction performing daily near-vision tasks.
conclusionsThe Hanita Intensity diffractive IOL successfully restores all distances of vision. The flat profile of the monocular defocus curve confirms the five-foci distribution principle that provides vision at all ranges while increasing the depth of focus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.